ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2259

Suppression of Monosodium Urate Crystal-Induced Cytokine Production Via Inhibition of Histone Deacetylases 1/2

Maartje Cleophas1, Tania Crisan2, Charles Dinarello3, M.G. Netea2 and Leo .A.B. Joosten2, 1Department of Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 2Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cytokines, gout and histone acetylation

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Innate Immunity and Rheumatic Disease - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Acute gout is a highly common and painful form of inflammatory arthritis, occurring mainly in men above the age of 50. The recurring flares of arthritis are elicited by monosodium urate (MSU) crystal deposits in the joints that, in the presence of a secondary stimulus, can induce synergistic cytokine production. Sodium butyrate can inhibit MSU-induced cytokine production via broad inhibition of class I histone deacetylases (HDACs)1, which includes HDAC1, -2, -3, and -8. HDACs could therefore be an important target for new therapies against gout. Our aim is to further pinpoint the HDAC(s) involved in MSU-induced cytokine production.

Methods: Primary peripheral blood mononuclear cells were isolated from healthy donors. The cells were pre-incubated with a highly specific HDAC1/2 inhibitor, Romidepsin, or other metabolic inhibitors and stimulated with a combination of palmitic acid (C16.0) and MSU crystals. Cytokine levels were measured by ELISA, transcription was measured with qPCR. In vivo effects of Romidepsin were assessed in C57Bl/6 mice. The mice received 2 intraperitoneal doses of Romidepsin, after which we injected them intra-articularly with a MSU crystals and a TLR2 ligand. Joint swelling was assessed macroscopically, IL-6 and KC were measured in the synovium, and total joints were sent for histology.

Results: Romidepsin potently inhibited C16.0+MSU-induced inflammatory cytokines in healthy volunteers. It furthermore induced transcription of PTEN, a negative regulator of PI3K/Akt signaling, and CPT1A, a β-oxidation enzyme that is down-regulated by Akt. Additionally, inhibiting glycolysis with 2-deoxy-D-glucose decreased C16.0+MSU-induced cytokine production, and inhibition of β-oxidation with etomoxir increased it. In vivo, Romidepsin potently inhibits macroscopic joint swelling already at a dose of 0.03 mg/kg. IL-6 and KC were not significantly reduced in the synovium. We are still awaiting the histology results.

Conclusion: These results suggest that Romidepsin inhibits MSU-induced cytokine production by restoring cellular energy homeostasis, possibly by inhibiting Akt signaling. In a relevant mouse model for gout, Romidepsin significantly inhibits macroscopic joint swelling. With these results, we provide a rationale for HDAC1/2 inhibition as a potent anti-inflammatory treatment which may have beneficial effects in acute gout.

References 1. Cleophas MC, Crisan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis 2015.


Disclosure: M. Cleophas, None; T. Crisan, None; C. Dinarello, None; M. G. Netea, European Research Council, 9; L. A. B. Joosten, None.

To cite this abstract in AMA style:

Cleophas M, Crisan T, Dinarello C, Netea MG, Joosten LAB. Suppression of Monosodium Urate Crystal-Induced Cytokine Production Via Inhibition of Histone Deacetylases 1/2 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/suppression-of-monosodium-urate-crystal-induced-cytokine-production-via-inhibition-of-histone-deacetylases-12/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppression-of-monosodium-urate-crystal-induced-cytokine-production-via-inhibition-of-histone-deacetylases-12/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology